

OncoTherapy Science, Inc.

February 15, 2018

Announcement of partnership between OTS's subsidiary company and  
Thermo Fisher Scientific to evaluate new liquid biopsy platform

OncoTherapy Science, Inc. (OTS) hereby announces that one of its subsidiary companies, Cancer Precision Medicine, Inc. (CPM) is partnering with Thermo Fisher Scientific to evaluate a new liquid biopsy platform.

CPM, a new biotechnology company in the sequencing analysis and development of personalized therapies for cancer patients in Japan, and Thermo Fisher, the world leader in serving science, have executed a material evaluation partnership agreement to evaluate recently launched products from Thermo Fisher's liquid biopsy portfolio. As part of the agreement, both organizations will work together to evaluate the Ion Torrent™ OncoPrint™ Pan-Cancer Cell-Free Assay in the analysis of blood samples collected from cancer patients.

Liquid biopsy, which analyzes tumor DNA and RNA from blood, has rapidly become a non-invasive alternative to sequencing tumor tissues. It also holds promise as a method to accelerate targeted clinical trials, selection of targeted therapy, disease monitoring, and evaluation of therapy response. In January 2018, Thermo Fisher launched the Ion Torrent OncoPrint Pan-Cancer Cell-Free Assay, which enables reproducible detection and analysis of tumor DNA and RNA across all major classes of somatic mutations (SNVs, indels, CNVs and fusions) targeting more than 50 genes across multiple cancer types, including lung, colorectal, breast, pancreatic, thyroid and others.

CPM provides next-generation sequencing analysis, prediction of neoantigen, liquid biopsy, TCR/BCR repertoire analysis, and immune monitoring, in order to accelerate cancer precision medicine in Japan. Particularly for liquid biopsy, CPM is collaborating with Itabashi Medical System (IMS) group, one of the major medical corporations in Japan, to apply the serial liquid biopsy tests in the clinic for the early detection of tumor recurrence as well as future applications in the cancer screening. In addition,

CPM conducts both research and development for the new type of personalized immunotherapy solutions, such as neoantigen-targeting dendritic cell therapy and TCR-engineered adoptive T cell therapy.

During this partnership, both organizations will work together to evaluate data and will address applications of liquid biopsy in the early detection of cancers. The long term goal of this partnership is to have ongoing cooperation between CPM and Thermo Fisher in areas ranging from improvement of technical platforms to rapid applications in the clinical fields.